Adalvo Expands Biosimilars Portfolio Through Acquisition of Romiplostim Biosimilar Program from Enzene

Adalvo announced on October 27, 2026 that it acquired Enzene’s romiplostim biosimilar program. The program references Amgen’s NPLATE®, which is indicated to treat adult and chronic pediatric immune thrombocytopenia (ITP)….
By: Goodwin